Study to evaluate the safety and the immunogenicity of a second generation structurally designed mRNA vaccine candidate against pandemic influenza H5 HA strain in healthy adult participants aged 18 years and older

Trial Identifier: VBS00002
Sponsor: Sanofi
Start Date: April 2025
Primary Completion Date: December 2026
Study Completion Date: December 2026
Condition: Healthy Volunteers; Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
UNITED STATES, California LA MESA, California, UNITED STATES, 91942
UNITED STATES, Florida DELAND, Florida, UNITED STATES, 32720
UNITED STATES, Florida LAKELAND, Florida, UNITED STATES, 33803
UNITED STATES, Florida Largo, Florida, UNITED STATES, 33777
UNITED STATES, Georgia DECATUR, Georgia, UNITED STATES, 30030-2627
UNITED STATES, Michigan BINGHAM FARMS, Michigan, UNITED STATES, 48334
UNITED STATES, Nebraska NORFOLK, Nebraska, UNITED STATES, 68701
UNITED STATES, Nebraska OMAHA, Nebraska, UNITED STATES, 68134
UNITED STATES, Ohio CINCINNATI, Ohio, UNITED STATES, 45246
UNITED STATES, South Carolina North Charleston, South Carolina, UNITED STATES, 29406
UNITED STATES, Texas SUGAR LAND, Texas, UNITED STATES, 77479
UNITED STATES, Utah WEST JORDAN, Utah, UNITED STATES, 84088
UNITED STATES, Virginia CHARLOTTESVILLE, Virginia, UNITED STATES, 22911